This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Ohara Pharmaceutical Co., Ltd.. Active years: 2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021
Title: Naoko Hattori: Innovator in Cancer Therapeutics
Introduction
Naoko Hattori is a prominent inventor based in Tokyo, Japan. She has made significant contributions to the field of cancer therapeutics, particularly through her innovative research and development of novel compounds.
Latest Patents
Hattori holds a patent for a DNMT inhibitor as a solid tumor therapeutic drug. This invention addresses the need for an effective medicine that can serve as a therapeutic or prophylactic drug for various advanced solid tumors. The compound is designed to have high stability against cytidine deaminase, allowing for oral administration and integration into nucleic acid biosynthetic pathways while inhibiting DNA methyltransferases (DNMTs).
Career Highlights
Throughout her career, Naoko Hattori has worked with notable companies, including Ohara Pharmaceutical Co., Ltd. and Toudai Tlo, Ltd. Her work has been instrumental in advancing therapeutic options for patients with high-risk myelodysplastic syndromes and other solid tumors.
Collaborations
Hattori has collaborated with esteemed colleagues such as Sako Magoichi and Toshikazu Ushijima. These partnerships have further enhanced her research and development efforts in the field of cancer therapeutics.
Conclusion
Naoko Hattori's innovative work in developing DNMT inhibitors showcases her commitment to improving cancer treatment options. Her contributions are paving the way for new therapeutic strategies in oncology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile